• Criptomonedas
  • Mercados de Predicción
  • Noticias
  • Trading Agéntico
  • Artículos
  • Ligas

Buscar Criptomonedas

Criptomonedas de tendencia

CoinRithm

Empresa

Entidad legal
Bees-x Limited
Número de empresa
13308136
Constituida en
England and Wales
Domicilio social
Monmouth House, High Street, Watford, England, WD17 1LN

CoinRithm es un servicio de información e investigación operado por Bees-x Limited. No está autorizado por la Financial Conduct Authority (FCA) para realizar actividades reguladas, y nada en este sitio constituye asesoramiento financiero.

Explorar

CriptomonedasMercados de PredicciónNoticiasArtículosAgent ArenaLigas

Funciones

TableroComercio SimuladoTrading AgénticoPortafolioLista de SeguimientoConfiguraciones

Empresa

Sobre NosotrosMetodologiaTérminos de UsoPolítica de PrivacidadPolítica de CookiesDescargo de Responsabilidad

Soporte

Contacto SoporteFAQKit para desarrolladoresDocumentación MCP

Sociales

X (Twitter)FacebookLinkedInTelegramInstagramTikTokYouTube
© 2026 CoinRithm. Reservados todos los derechos.
Disponible en Google PlayDescargar en App Store
  • Inicio
  • MercadosMercados de Predicción
  • Noticias
  • Tablero
  1. Mercados de Predicción
  2. Health & Medicine
  3. What will the phase 3 clinical trial results report for vaccine efficacy (%) of the R21 malaria vaccine at 48 months?
Manifold Markets

What will the phase 3 clinical trial results report for vaccine efficacy (%) of the R21 malaria vaccine at 48 months?

Health & MedicineOne-Off2m
Manifold MarketsManifold MarketsSin KYC
Pronóstico comunitario actual
Manifold Markets
20-29% 9.4%
Líder entre 7 opciones
Pronosticadores

11

Tipo de pregunta

multiple choice

Metodología

Play-money forecasting platform

Tipo de fuente

Pronóstico

Datos de mercado

Actualizado anteayer

Desactualizado
15 mar 24, 21:292 sept 26, 6:59

Tendencias

Resultado24hProbabilidad

Resultado elegido

20-29%9%

Reglas

The 12 month phase 3 data indicates 75% vaccine efficacy of R21 in annual malaria sites in children at 12 months after the first dose was delivered.

Manifold Markets
  • Phase 2b data at a 42 month timepoint showed 71% efficacy after four total doses (Abstract here, #6949).
  • Resolves upon publication of peer-reviewed data from the R21 team at Oxford (expected to be before September 1st, 2026).
  • Vaccine efficacy is defined as the primary endpoint for time to clinical malaria in seasonal sites, as defined in the paper linked above.
  • 1Day Sooner has an R21 Status Report available here that may be useful.
  • More malaria-related questions can be found on our Manifold account here.

Mercados Relacionados

Hantavirus pandemic in 2026?

Hantavirus pandemic in 2026?

145,3 mil €
Sí: 5%PolymarketPOLYMARKET
New pandemic in 2026?

New pandemic in 2026?

16,6 mil €
Sí: 10%PolymarketPOLYMARKET
Ebola pandemic in 2026?

Ebola pandemic in 2026?

8,7 mil €
Sí: 8%PolymarketPOLYMARKET
Manifold Markets

How many movies will gross >$1 billion in 2026?

1,3 mil €
0-3: 5.7%Manifold MarketsMANIFOLD MARKETS
Manifold Markets

Which disease will be eradicated next in humans?

462,5 €
Polio: 26.7%Manifold MarketsMANIFOLD MARKETS
When, where or how will Trump die?

When, where or how will Trump die?

137,8 €
2025: 0%Manifold MarketsMANIFOLD MARKETS

Activos en estos temas

BitcoinBTC$62,928.32+2.44%EthereumETH$1,659.49+1.68%SolanaSOL$65.34+1.62%DogecoinDOGE$0.085+1.53%XRPXRP$1.12+0.39%BNBBNB$596.89+1.78%

Noticias Relacionadas

Chainalysis reveals $100 million peptide market built on cryptoCrypto NewsGray peptide vendors embrace stablecoins as safety fears deepenCrypto NewsOpenAI Expands GPT-Rosalind Access with Rosalind BiodefenseBlockchain.NewsOpenAI Expands GPT-Rosalind Capabilities for Life SciencesBlockchain.NewsBrian Armstrong’s NewLimit Raises $435M for Human TrialsCrypto News

Reglas

The 12 month phase 3 data indicates 75% vaccine efficacy of R21 in annual malaria sites in children at 12 months after the first dose was delivered.

Manifold Markets
  • Phase 2b data at a 42 month timepoint showed 71% efficacy after four total doses (Abstract here, #6949).
  • Resolves upon publication of peer-reviewed data from the R21 team at Oxford (expected to be before September 1st, 2026).
  • Vaccine efficacy is defined as the primary endpoint for time to clinical malaria in seasonal sites, as defined in the paper linked above.
  • 1Day Sooner has an R21 Status Report available here that may be useful.
  • More malaria-related questions can be found on our Manifold account here.